A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).

被引：0
|
作者：
Schlumberger, Martin
Jarzab, Barbara
Cabanillas, Maria E.
Robinson, Bruce
Pacini, Furio
Ball, Douglas Wilmot
McCaffrey, Judith C.
Newbold, Kate
Allison, Roger
Martins, Renato
Licitra, Lisa F.
Shah, Manisha H.
Bodenner, Donald
Elisei, Rossella
Burmeister, Lynn A.
Funahashi, Yasuhiro
Sellecchia, Rita
Andresen, Corina
O'Brien, James P.
Sherman, Steven I.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland
[3] Inst Oncol, Gliwice, Poland
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Royal N Shore Hosp, St Leonards, NSW 2065, Australia
[6] Azienda Osped Univ Senese, Siena, Italy
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[9] Royal Marsden Hosp, Sutton, Surrey, England
[10] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[11] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[12] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[13] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA
[14] Ohio State Univ, Ctr Comprehens Canc, Solove Res Inst, Columbus, OH 43210 USA
[15] Univ Arkansas, Little Rock, AR 72204 USA
[16] Univ Pisa, Pisa, Italy
[17] Univ Minnesota, Minneapolis, MN USA
[18] Eisai, Andover, MA USA
[19] European Knowledge Ctr, Hatfield, Herts, England
[20] Eisai, Woodcliff Lake, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5591
引用
收藏
页数：1
相关论文
共 50 条
  • [21] E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
    Wiegering, Armin
    Korb, Doreen
    Thalheimer, Andreas
    Kaemmerer, Ulrike
    Allmanritter, Jan
    Matthes, Niels
    Linnebacher, Michael
    Schlegel, Nicolas
    Klein, Ingo
    Erguen, Sueleyman
    Germer, Christoph-Thomas
    Otto, Christoph
    NEOPLASIA, 2014, 16 (11): : 972 - 981
  • [22] Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
    Hong, David S.
    Kurzrock, Razelle
    Falchook, Gerald S.
    Andresen, Corina
    Kwak, Jennifer
    Ren, Min
    Xu, Lucy
    George, Goldy C.
    Kim, Kevin B.
    Nguyen, Ly M.
    O'Brien, James P.
    Nemunaitis, John
    ONCOTARGET, 2015, 6 (40) : 43127 - 43134
  • [23] Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
    Tohyama, Osamu
    Matsui, Junji
    Kodama, Kotaro
    Hata-Sugi, Naoko
    Kimura, Takayuki
    Okamoto, Kiyoshi
    Minoshima, Yukinori
    Iwata, Masao
    Funahashi, Yasuhiro
    JOURNAL OF THYROID RESEARCH, 2014, 2014
  • [24] Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
    Enomoto, Keisuke
    Hirayama, Shun
    Kumashiro, Naoko
    Jing, Xuefeng
    Kimura, Takahito
    Tamagawa, Shunji
    Matsuzaki, Ibu
    Murata, Shin-Ichi
    Hotomi, Muneki
    CANCERS, 2021, 13 (04) : 1 - 14
  • [25] An analysis of the baseline characteristics and outcomes, by responders and nonresponders, from the phase 3 study of (E7080) Lenvatinib in differentiated cancer of the thyroid (SELECT)
    Reuter, Christoph
    Yu, Xiaomin
    Baig, Mahadi
    Young, Louise
    Dutcus, Corina
    CLINICAL ENDOCRINOLOGY, 2018, 89 : 45 - 46
  • [26] A PHASE I AND DOSE-FINDING STUDY OF LENVATINIB (E7080) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Nokihara, H.
    Yamada, Y.
    Honda, K.
    Wakui, H.
    Sasaki, T.
    Yusa, W.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2013, 24
  • [27] A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma
    O'Day, Steven
    Gonzalez, Rene
    Kim, Kevin
    Chmielowski, Bartosz
    Kefford, Richard
    Long, Georgina
    Loquai, Carmen
    Cowey, Charles Lance
    Hauschild, Axel
    Hainsworth, John D.
    Hersey, Peter
    Boyle, Frances
    Evans, T. R. Jeffry
    Hamid, Omid
    Meneses, Nicole
    Andresen, Corina
    Ren, Min
    O'Brien, James P.
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] ANALYSES OF A PHASE 3, MULTICENTER, DOUBLEBLIND, PLACEBO- CONTROLLED TRIAL OF LENVATINIB (E7080) IN PATIENTS WITH 131-I-REFRACTORY DIFFERENTIATED THYROID CANCER (SELECT)
    不详
    EUROPEAN THYROID JOURNAL, 2014, 3 : 12 - 250
  • [29] A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-refractory differentiated thyroid cancer (SELECT)
    Schlumberger, M.
    Tahara, M.
    Wirth, L.
    Robinson, B.
    Brose, M.
    Elisei, R.
    Dutcus, C.
    de las Heras, B.
    Zhu, J.
    Habra, M.
    Newbold, K.
    Shah, M. H.
    Hoff, A. O.
    Gianoukakis, A. G.
    Kiyota, N.
    Taylor, M.
    Kim, S-B
    Krzyzanowska, M.
    Sherman, S., I
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 119 - 119
  • [30] A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Molina, Ana M.
    Hutson, Thomas E.
    Larkin, James
    Gold, Anne M.
    Wood, Karen
    Carter, Dave
    Motzer, Robert
    Michaelson, M. Dror
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 181 - 189
12345